Single-use filtration assemblies market seen reaching $11.76 billion by 2030

The Business Research Company says the single-use filtration assemblies market is set to grow from $5.56 billion in 2025 to $11.76 billion by 2030, driven by biopharmaceutical manufacturing, contamination control and broader adoption of disposable technologies. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Single-use filtration assemblies are becoming a core tool in biopharmaceutical production, where contamination control, speed and flexibility affect manufacturing output. - The market’s projected jump to $11.76 billion by 2030 signals continued investment in disposable filtration systems across drug development, cell and gene therapy, and laboratory workflows.

What happened: - The Business Research Company projected the global single-use filtration assemblies market will rise from $5.56 billion in 2025 to $6.44 billion in 2026. - The firm forecasts the market will reach $11.76 billion by 2030, implying a 16.3% compound annual growth rate from 2026 to 2030. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also released a free sample report and a full market report online: More information and the full report.

The details: - Single-use filtration assemblies are disposable systems that combine filters, housings, connectors and tubing in a pre-assembled, sterilized format. - The assemblies are used in biopharmaceuticals, food and beverage production and laboratory research. - The market’s recent growth has been supported by higher biologics and vaccine production, broader use of disposable downstream processing, greater use of filtration in laboratory settings and the expansion of contract bioprocessing services. - The forecast through 2030 is tied to demand for scalable bioprocessing systems, stronger contamination prevention, growth in cell and gene therapy manufacturing, investment in advanced filtration materials and wider use of continuous bioprocessing. - The report highlights rising use of pre-assembled filtration systems, demand for sterile single-use filtration, broader use in biopharmaceutical manufacturing, development of high-capacity filtration assemblies and a stronger focus on process efficiency and validation.

Between the lines: - The market outlook reflects a larger shift in biomanufacturing toward disposable, ready-to-use systems that reduce cleanup and lower contamination risk. - Biopharmaceutical research spending is an important demand driver because single-use filtration assemblies help remove cells and debris during development and production. - The Society of Chemical Industry said UK cell and gene therapy companies secured about £200 million in venture capital funding in 2023, supporting 47 clinical trials launched in 2024 and helping the UK recruit 9.5% of global advanced therapy trial participants. - That funding example points to how capital-intensive advanced therapies can translate into more demand for filtration infrastructure.

What's next: - The market is expected to keep expanding as cell and gene therapy manufacturing scales and as more producers adopt continuous bioprocessing. - The Business Research Company says future reports will include expanded capabilities such as TAM analysis, company scoring matrix graphics, forecasting dashboards, market hotspots infographics and updated trend analysis. - The company lists Saumya Sahay as a contact for more information.

The bottom line: - Single-use filtration assemblies are moving from a niche process tool to a larger manufacturing standard, and the market’s forecast growth shows that shift is still accelerating.